Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH
Laura Giuseppina Di Pasqua, Marta Cagna, G. Palladini, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 214-227
Open Access | Times Cited: 11

Showing 11 citing articles:

Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets
Joshua S. Fleishman, Sunil Kumar
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases
Yanyan Wang, Huangru Xu, Xiqiao Zhou, et al.
Medical Review (2024) Vol. 4, Iss. 4, pp. 262-283
Open Access | Times Cited: 6
Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population
Jingjing Ding, Huaizheng Liu, Xiaoxun Zhang, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 772
Closed Access | Times Cited: 5
RECK as a Potential Crucial Molecule for the Targeted Treatment of Sepsis
Yuting Qin, Shuanglin Liao, Jianbo Sun, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 1787-1813
Open Access
Advances in research on metabolic dysfunction-associated steatotic liver disease
Jiawang Wang, Zhongyu Wang, Yao Yu, et al.
Life Sciences (2025) Vol. 362, pp. 123362-123362
Closed Access
Patented Farnesoid X receptor modulators: a review (2019 – present)
Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 7, pp. 547-564
Closed Access | Times Cited: 3
Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries
G. Palladini, Laura Giuseppina Di Pasqua, Anna Cleta Croce, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17407-17407
Open Access | Times Cited: 3
Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis
Luciano Adorini, Kristoffer T. G. Rigbolt, Michael Feigh, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0300809-e0300809
Open Access
Bile Acids and Liver Cancer: Molecular Mechanism and Therapeutic Prospects
Xuemei Zhang, Lei Shi, Xiaona Lu, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1142-1142
Open Access
A Comparative Analysis of ADRs under Obeticholic Acid and Ursodeoxycholic Acid in Cholestatic Liver Diseases Using the FAERS Database
Meng Qing Zhu, Linghui Tao, Feiye Zhu, et al.
Drug Research (2024)
Closed Access
Restoration of RECK expression attenuates liver fibrosis induced by carbon tetrachloride through the Nrf2–MMP9 axis
Bizhen Wei, Jing Huang, Yu Zhang, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113475-113475
Open Access
Page 1

Scroll to top